Symibs: a new class of designer intrabodies for the development of anticancer treatments targeting unstructured protein domains of MYC and p53. KU Leuven
This project will combine protein engineering, structural biology and molecular cell biology methods to engineer the computationally designed SAKe proteins into Symibs. Symibs, or Symmetric intrabodies, may form a novel class of intrabodies capable of targeting disordered peptide motifs, which are currently out of reach for the current preferred intrabody scaffolds (nanobodies or DARPins). Symibs will serve to detect, bind and neutralize ...